Stocks making the biggest moves premarket: Fiserv, Crinetics Pharmaceuticals, Micron & more
The headline highlights several stocks making significant premarket moves, including Fiserv, Crinetics Pharmaceuticals, and Micron. This generic 'biggest movers' report often signals underlying catalysts for individual names, prompting a closer look at the drivers behind each stock's early trading activity.
CNBC's premarket movers list points to several companies experiencing notable price action before the market open. While the headline itself is broad, it typically indicates that specific news or events are impacting these individual stocks, ranging from earnings reports to analyst upgrades/downgrades or company-specific announcements.
Crinetics Pharmaceuticals (CRNX) is one such name, showing a massive 640.7% year-over-year revenue growth, albeit from a small base of $7.7 million. However, this growth comes with significant unprofitability, evidenced by a -6046.0% net margin and a diluted EPS of -$4.95, indicating it is a high-growth, high-burn biotech.
Micron Technology (MU) is also on the list, reporting robust revenue of $37.4 billion, up 48.9% year-over-year, with healthy gross margins of 39.8% and net margins of 22.8%, translating to a diluted EPS of $7.59. Micron's performance is often a bellwether for the broader semiconductor memory market.
The premarket movements suggest that investors are reacting to specific news for each company. For CRNX, the focus would likely be on clinical trial data or funding rounds, given its early-stage financial profile. For MU, the movement could be tied to demand outlook for memory chips, particularly in AI and data center segments, or competitive dynamics.
Investors are weighing the premarket moves of Crinetics Pharmaceuticals (CRNX) and Micron (MU), assessing whether their underlying fundamentals justify the early price action.
This is a pair trade capitalizing on the divergent risk/reward profiles of a high-growth, unprofitable biotech (CRNX) versus a profitable, cyclical semiconductor giant (MU). The premarket mention, while vague, indicates potential volatility that can be exploited by going long the more stable, profitable growth story and shorting the speculative play, particularly given CRNX's massive negative margins and EPS.
A major positive clinical trial readout for CRNX or an unexpected downturn in chip demand for MU could unwind this trade. CRNX's high volatility means any positive news could trigger a significant short squeeze.
CoverageSource: CNBC · Published here WED, JUL 8 · 8:47 AM ET · 2 reports · 1 publisher in this record · latest listed: CNBC · WED, JUL 8 · 8:47 AM ETHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
Micron (MU) presents a strong bull case with robust revenue growth of 48.9% YoY and solid profitability (22.8% net margin, $7.59 diluted EPS), indicating a healthy position in the recovering semiconductor cycle.
Crinetics Pharmaceuticals (CRNX) faces a significant bear case due to its substantial unprofitability, with a staggering -6046.0% net margin and -$4.95 diluted EPS, despite high revenue growth, highlighting its cash burn and speculative nature.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →